The report looked good to me. I don't see any reason for it being down in after hours.
lets see the low end of guidance they lowered when they have consistently beaten the high end --by 5% plus for quite a while....stupid people selling is what i see.... just hold on will recoup this 2-3% within a week or two and be well above 180...i see 200 by year end ...but thats just my humble opinion
Like Shep cant find why it is down? either some big players have sold or they have bad guidance?
Finally closed above $180 with earnings coming soon and all the new FDA information we should seeing big gains soon.
AMGN mentioned, along with ACRX; ACRX today traded 27 x the 3 month daily Volume Average... ACRX started as a Buy, with 255% upside; AMGN, ACRX mentioned....
Trouble at the Nasdaq Mothership. Must be those pesky Ruskies again!
Apple, Google and other Nasdaq Stocks Swing Wildly in After-Hours Trading
The prices of shares in some of the world’s biggest companies seemed to alternately plummet or soar in after-hours trading on Nasdaq Inc.’s flagship exchange.
Please tell me amgn split 2:1 today....
IGXT (MC $50 M) NDA filing for MEGA thin-flim Cialis (better than Viagra) this month =10++ BAGGER Potential ! PLEASE read this guys and then join us to make big money .A LIFETIME OPPORTUNITY HERE GUYS !!!
2 US-NDA submission within 2 months ,lot of Cash and heavily underpriced at a valuation of just $50 million .1 Big drug partnered with Endo Pharma already under review by FDA market launch expected in 1H 2018 .GL
MarketCap $50 Million Cash ~$12 Million (including convertible debt) =cash untill 2021+ Price: 0.80
NDA submission for tadalafil (erectile dysfunction) thin-film version of Blockbuster drug Cialis in June or July NDA resubmission for Rizaport (migraine) in early Q3 Partnership for Tadalafil in 2H 2017
IntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020. IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition.
Tadalafil is an erectile dysfunction (ED) treatment that boasts bioequivalence with Cialis, the current leading brand, and with a successful biostudy in-hand a 505(b)(2) NDA is set to be filed any day now, meaning that a full launch should be expected in mid-2018. Cialis is already winning-out over Viagra in terms of numbers of prescriptions, which is largely down to price and efficacy, but when Tadalafil comes to market with the same product in a more convenient and discreet delivery mechanism, IntelGenX should see a massive number of customers take-up its services.
IntelGenx has multi-faceted BD approach for its oral films
With a burgeoning pipeline of pharmaceutical oral films, IntelGenx’s (OTCQX:IGXT; TSXV:IGX) business development strategy is focused on partnering its product pipeline along with actively meeting with potential partners to explore manufacturing
amgn has formed a right cup with handle = super bullish!
whooz yor daddy
So what's gonna happen to biotechs if this aca healthcare bill can't get past the Senate?
Heading for a new 52 week high. Get onboard now before you miss out.